{"id":390839,"date":"2017-11-27T00:00:00","date_gmt":"2017-11-27T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfcg0005-2017-biopharma-parkinsons-disease-disease-landscape-and-forecast-g7-2017\/"},"modified":"2026-04-24T05:26:03","modified_gmt":"2026-04-24T05:26:03","slug":"dlsfcg0005-2017-biopharma-parkinsons-disease-disease-landscape-and-forecast-g7-2017","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfcg0005-2017-biopharma-parkinsons-disease-disease-landscape-and-forecast-g7-2017\/","title":{"rendered":"Parkinson&#8217;s Disease | Disease Landscape and Forecast | G7 | 2017"},"content":{"rendered":"<p>The Parkinson\u2019s disease (PD) market is in the midst of transformation: the first new levodopa formulation (Rytary) in over a decade has launched with more on the horizon (e.g.,\u00a0ND-0612,\u00a0AP-CD\/LD), two new rescue therapies for \u201coff\u201d periods will be available within the next three years (i.e., CVT-301 and\u00a0APL-130277), and several new adjunctive agents for motor and nonmotor symptoms have launched (i.e., Xadago, Ongentys, Nuplazid, and Gocovri) or are in late-phase development (e.g., OS-320, HP-3000). These and other product launches will add another layer of complexity to an already complicated treatment algorithm with the potential to meaningfully increase\u00a0sales in the\u00a0PD\u00a0market. However, given the cost-sensitivity of\u00a0PD\u00a0patients and widespread availability of generic and\u2014for many patients\u2014therapeutically adequate agents, new\u00a0PD\u00a0brands will enter a market of intensifying competition and access challenges.<\/p>\n<p><strong>QUESTIONS ANSWERED :<\/strong><\/p>\n<ul>\n<li>What will be the impact of anticipated levodopa reformulations? Will they experience rapid uptake and alter the\u00a0PD\u00a0treatment paradigm, or will access hurdles and\/or physician resistance limit use?<\/li>\n<li>What is the market opportunity for recently launched and emerging agents targeting key nonmotor symptoms in\u00a0PD?<\/li>\n<li>How will neurologists differentiate among current and next-generation levodopa-adjunct therapies for motor fluctuations and dyskinesia, and which therapies will enjoy the greatest clinical and commercial success in the face of generics competition in the\u00a0PD\u00a0market?<\/li>\n<\/ul>\n<p><strong>PRODUCT DESCRIPTION:<\/strong><\/p>\n<p>Disease Landscape &#038; Forecast: Comprehensive market intelligence providing world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.<\/p>\n","protected":false},"template":"","class_list":["post-390839","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-parkinsons-disease","biopharma-date-890"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390839","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390839\/revisions"}],"predecessor-version":[{"id":576790,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390839\/revisions\/576790"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390839"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}